Navigation Links
CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
Date:2/16/2012

ases that affect fewer than 200,000 people in the U.S. Orphan designation qualifies the sponsor of the product for important tax credits, elimination of FDA license application fees and certain marketing incentives.

CSL Behring's rVIIa-FP was granted Orphan Drug Designations (ODD) by the European Commission in May, 2011.

About Hemophilia
Hemophilia is a congenital bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. In nearly all cases, it affects only males. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective.  Hemophilia B is characterized by deficient or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for patients who are factor deficient is to treat by replacement factor therapy. A complication in some patients is the development of inhibitory antibodies (inhibitors) to FVIII or FIX which renders replacement therapy ineffective.  This can occur in up to 25 percent of hemophilia A patients and around 5 percent of hemophilia B patients.  One treatment option for these patients is recombinant activated factor VII (called a bypassing agent) which can be used to achieve hemostasis without the need for factor VIII or IX. 

About the recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
Preclinical studies have confirmed that CSL Behring's rVIIa-FP has favorable pharmacokinetic properties compared with the existing recombinant FVIIa product.
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
2. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
3. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
4. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
5. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
6. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
9. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
10. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
(Date:5/4/2015)... DOYLESTOWN, Pa. , May 4, 2015  Makindus, ... announced today that the European Medicines Agency (EMA) has ... for the treatment of Stargardt,s Disease. "We ... for MI-100 to treat Stargardt,s disease in place for ... our development program in the United States ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3European Medicines Agency (EMA) Grants Orphan Designation for Makindus' MI-100 for Stargardt's Disease 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... Delcath Systems, Inc. (Nasdaq: DCTH ) announced ... discuss its recent corporate developments and update its progress on ... President and Chief Executive Officer will host the call. ... 800-322-5044 for domestic participants and 617-614-4927 for international participants, both ...
... 2011 CVS Caremark Corporation (NYSE: CVS ... present at two investor conferences in the month of ... CVS Caremark, will be making a presentation to investors ... on Thursday, November 10th, at approximately 10:00 a.m. MST ...
Cached Medicine Technology:Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 2Delcath Systems to Report Third Quarter Progress and Conduct Conference Call 3CVS Caremark to Present at Upcoming Conferences 2
(Date:5/4/2015)... Each year, the Susan G. Komen organization hosts ... for breast cancer. This year, Dr. Mark Deutsch and his ... entertainment sponsor for the 25th annual Susan G. Komen Greater ... Lenox Square Mall. , The Komen organization hopes have 10,000 ... million. Perimeter Plastic Surgery has not only taken on the ...
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... 04, 2015 The opportunity for children to ... are the motivating forces behind The Fairy Godmother Next Door, ... author Amy L. Stark. , The inspiration for the enchanting ... door comes from Stark’s desire to be a fairy godmother. ... fairy godmother to my neighbors’ children since they were born. ...
(Date:5/4/2015)... May 04, 2015 The U.S. healthcare ... boomers join the ranks of senior citizens (1) and ... an already over-burdened healthcare system. Additionally, as older healthcare ... replace them. Per the U.S. Census Bureau, the number ... increase 75% by 2050 while those 25 to 54 ...
(Date:5/4/2015)... WA (PRWEB) May 04, 2015 EyeCRO ... a collaboration to facilitate development of NM108, a first-in-class ... that lead to blindness, including Diabetic Retinopathy. The ... platform developed by EyeCRO, which can deliver drugs to ... topical eyedrop. , Under the terms of the ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3
... (FEW) salutes the House of Representatives for approving ... federal worker provisions. An amendment was offered by ... include the Federal Employees Retirement System (FERS) Sick ... mark up of the bill. Subcommittee member Rep. ...
... levels rise in the wake of climate change and ... parts of the world are likely to be displaced. ... International Journal of Mathematics and Operational Research . ... Lethbridge, Alberta, Canada, and colleagues Ruhul Sarker of the ...
... Now Available to Other Food ManufacturersCHICAGO, April 1 ... new satiety water in New Zealand, called Whole. ... is a first for the market, and food ... other global markets can currently leverage the product,s ...
... Industry Leaders from Across the Country Gather to ... Performance ImprovementALEXANDRIA, Va., April 1 ... Care (IPC) solutions, recently concluded its highly successful ... for the GetWellNetwork community, GetConnected2009 ...
... Efforts are Rewarded for Third Consecutive YearOAKLAND, Calif., ... a "Climate Action Leader" for voluntarily calculating, verifying ... the California Climate Action Registry. This is the ... award from the Registry, a private, nonprofit organization ...
... Australian study suggests link to modifiable maternal habit, , , ... has replaced infants sleeping on their stomachs as the ... or SIDS, Australian researchers suggest. , They found that ... which awakens them in response to a life-threatening situation, ...
Cached Medicine News:Health News:FEW Salutes House for Passing Legislation with Federal Worker Provisions; FERS Sick Leave Credit and FERS Redeposit Approved 2Health News:FEW Salutes House for Passing Legislation with Federal Worker Provisions; FERS Sick Leave Credit and FERS Redeposit Approved 3Health News:Relocation, relocation, relocation 2Health News:Fonterra's New ClearProtein(TM) Satiety Water a First for New Zealand Market 2Health News:Fonterra's New ClearProtein(TM) Satiety Water a First for New Zealand Market 3Health News:Innovation and Sharing of Client Successes Highlight GetWellNetwork's GetConnected2009 Conference 2Health News:Innovation and Sharing of Client Successes Highlight GetWellNetwork's GetConnected2009 Conference 3Health News:Innovation and Sharing of Client Successes Highlight GetWellNetwork's GetConnected2009 Conference 4Health News:Kaiser Permanente Recognized for Efforts to Spread Health by Curbing Climate Change 2Health News:Kaiser Permanente Recognized for Efforts to Spread Health by Curbing Climate Change 3Health News:Kaiser Permanente Recognized for Efforts to Spread Health by Curbing Climate Change 4Health News:Mom's Smoking May Lead to SIDS 2
Fahlbusch hypophysectomie instrument, spoon, bayonet-shaped, malleable....
... is pouncing on the T.L.I.F. market as the ... of CFRP clinical history and the amazing success ... Leopard is sure to be king of the ... from 7-18 mm in height. The footprint is ...
... Cage System provides anterior column support for ... from T1 to L5. The system consists ... Polymer cages that are stacked to a ... Peek Carbon Fiber Reinforced Polymer material emulates ...
... Jaguar Lumbar I/F Cage system is a ... separate the mechanical and biologic functions of ... Lumbar I/F Cage provides a device designed ... and uses autologous cancellous bone, the best ...
Medicine Products: